In a report released yesterday, Daniil Gataulin from Chardan Capital maintained a Hold rating on Kodiak Sciences, with a price target of $14.00. The company’s shares closed last Friday at $15.06.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Gataulin is an analyst with an average return of -7.5% and a 34.09% success rate. Gataulin covers the Healthcare sector, focusing on stocks such as uniQure, Ocular Therapeutix, and Clearside Biomedical.
Currently, the analyst consensus on Kodiak Sciences is a Hold with an average price target of $13.00, which is a -13.68% downside from current levels. In a report released on September 25, Barclays also upgraded the stock to a Hold with a $17.00 price target.
KOD market cap is currently $795.5M and has a P/E ratio of -3.97.
Read More on KOD:
Disclaimer & DisclosureReport an Issue
- Kodiak Sciences upgraded to Equal Weight from Underweight at Barclays
- Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz
- Promising Drug Pipeline and Strong Financial Position Drive Buy Rating for Kodiak Sciences
- Kodiak Sciences initiated with a Buy at Jefferies
- Kodiak Sciences announces new data from APEX study of KSI-101
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)
